Celltrion announced on the 16th that it confirmed its efficacy in animal efficacy tests for delta mutation virus of Corona 19 (COVID-19) antibody treatment 'Regkirona’(CT-P59).
BPOM Immediately Gives Emergency Permit for Covid-19 Drug, Regdanvimab(CT-P59).
Read the CNN Indonesia article "BPOM Immediately Gives Emergency Permit for Covid-19 Drug Regdanvimab" in full here: https://t.co/a6ZuNAYjwG covid-19-regdanvimab.
Celltrion announced on the 12th that it has announced the results of Phase 3 clinical trials of Regkirona(CT-P59), an antibodies treatment for Corona 19, at the 31st European Society of Clinical Microbiology and Infectious Diseases (ECCMID).
Celltrion's corona 19 antibody treatment, Rekirona(Regdanvimab), showed efficacy against gamma mutation virus in animal testing. The survival rate of the administered group was 100%(55mice used). The result of Delta mutation comming soon. https://t.co/pQ7N68lKRA